ELDN

Eledon Pharmaceuticals Inc

2.48

Oct 21 • 5:21 AM ET +0.22 (9.98%)

Healthcare Biotechnology USA Micro NASD

Peers: TNXP BMY ZURA SNY RNAC AMGN VERA CDNA AMLX NTRA

| Held by: VTI IWM VXF IWO VTWO DFAS IWC GSSC VTWG FESM

Index	RUT
Market Cap	201.52M
Enterprise Value	152.25M
Income	-98.56M
Sales	0.00M
Book/sh	0.41
Cash/sh	1.09
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	33
IPO	Sep 17, 2014

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	6.08
P/C	2.27
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	7.90
Current Ratio	7.90
Debt/Eq	0.01
LT Debt/Eq	0.00
Option/Short	Yes / Yes

EPS (ttm)	-0.99
EPS next Y	-0.83
EPS next Q	-0.19
EPS this Y	-82.69%
EPS next Y	12.63%
EPS next 5Y	-17.33%
EPS past 3/5Y	55.10% 48.72%
Sales past 3/5Y	- -
EPS Y/Y TTM	-1475.42%
Sales Y/Y TTM	-
EPS Q/Q	-91.47%
Sales Q/Q	-
Earnings	Aug 13 AMC
EPS/Sales Surpr.	-70.89% -

Insider Own	1.02%
Insider Trans	0.00%
Inst Own	62.51%
Inst Trans	6.47%
ROA	-72.74%
ROE	-110.71%
ROIC	-136.67%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	2.23%
SMA50	-12.65%
SMA200	-19.54%
Trades

Shs Outstand	80.89M
Shs Float	80.43M
Short Float	9.76%
Short Ratio	8.56
Short Interest	7.85M
52W High	4.60 -46.09%
52W Low	1.35 83.70%
Volatility	8.24% 6.61%
ATR (14)	0.16
RSI (14)	48.05
Beta	0.98
Rel Volume	0.00
Avg Volume	916.72K
Volume	22

Perf Week	10.22%
Perf Month	-14.19%
Perf Quarter	-33.69%
Perf Half Y	-37.84%
Perf YTD	64.24%
Perf Year	-28.94%
Perf 3Y	90.77%
Perf 5Y	-54.07%
Perf 10Y	-98.90%
Recom	1.00
Target Price	9.50
Prev Close	2.26
Price	2.48
Change %	9.98%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-18-25	Resumed	H.C. Wainwright	Buy	$9
Jan-28-25	Initiated	Guggenheim	Buy	$9
May-13-22	Resumed	Cantor Fitzgerald	Overweight	$25 → $15
Mar-23-21	Initiated	Cantor Fitzgerald	Overweight	$25

Oct-05-26 04:05PM	Eledon Pharmaceuticals Announces Presentation at the American Society of Nephrology Kidney Week 2026 Annual Meeting (GlobeNewswire)
Sep-22-26 07:00AM	Eledon Presents Updated Long-Term Phase 2 BESTOW Extension Study Results at the International Congress of The Transplantation Society (GlobeNewswire) +7.43%
Sep-09-26 07:00AM	Eledon Pharmaceuticals Announces Presentation at the International Congress of The Transplantation Society (GlobeNewswire)
Sep-03-26 07:00AM	Eledon Pharmaceuticals Announces Islet Cell Transplantation IND Submission, First Patients Enrolled in Multiple Transplant Programs, and Reaffirms Plan to Initiate Phase 3 Kidney Transplantation Trial in Fourth Quarter 2026 (GlobeNewswire)
Aug-13-26 04:05PM	Eledon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Business Highlights (GlobeNewswire)
09:00AM	Loading…
Jul-21-26 09:00AM	A Diabetes Therapy Just Locked In Its Cell Supplier, and the Race to End Insulin Injections Is Heating Up (PR Newswire)
Jul-08-26 09:00AM	The Longevity Protein Race Reaches Manufacturing: One Microcap Just Completed A GMP Master Cell Bank For Its Anti-Aging Klotho Therapy (PR Newswire) +7.12%
Jun-25-26 07:00AM	Natera and Eledon Announce Strategic Partnership for Prospera Monitoring in Planned Phase 3 Kidney Transplant Trial (Business Wire) -7.83%
Jun-22-26 07:00AM	Eledon Presents Long-Term Extension Phase 2 BESTOW Results at American Transplant Congress Showing Sustained Higher Kidney Function and Improved Patient-Reported Outcomes with Tegoprubart Compared with Tacrolimus (GlobeNewswire)
Jun-08-26 07:00AM	Eledon Announces Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes (T1D) at UChicago Medicine (GlobeNewswire)
Jun-04-26 04:31PM	Eledon Announces Presentation of Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes at American Diabetes Association (ADA) 2026 Scientific Sessions (GlobeNewswire) -5.28%
May-20-26 04:05PM	Eledon Pharmaceuticals to Present New Long-Term Data from Phase 2 BESTOW Trial of Tegoprubart for the Prevention of Rejection in Kidney Transplantation at American Transplant Congress (GlobeNewswire) +7.26%
May-13-26 04:05PM	Eledon Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Business Highlights (GlobeNewswire)
Mar-19-26 05:10PM	Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Operating and Financial Results (GlobeNewswire) -5.00%
Mar-16-26 07:00AM	Eledon Announces Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes at UChicago Medicine (GlobeNewswire)
07:00AM	Loading…
Mar-10-26 07:00AM	Eledon Pharmaceuticals Announces Orphan Drug Designation Granted to Tegoprubart for the Prevention of Allograft Rejection in Liver Transplantation (GlobeNewswire)
06:53AM	NewcelX and Eledon partner for NCEL-101 programme (Pharmaceutical Technology)
Mar-04-26 04:05PM	Eledon Pharmaceuticals to Participate in Leerink Partners 2026 Global Healthcare Conference (GlobeNewswire)
Feb-13-26 12:34PM	Eledon Pharmaceuticals Highlights BESTOW Data, Phase III Plans and FDA Timeline for Tego at Conference (MarketBeat)
Feb-05-26 04:10PM	Eledon Pharmaceuticals to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 (GlobeNewswire) -8.37% +11.17%
Jan-23-26 07:00AM	Eledon Pharmaceuticals Presents Long-Term Phase 1b Data for Tegoprubart in Kidney Transplant Patients at the American Society of Transplant Surgeons Winter Symposium (GlobeNewswire)
Jan-08-26 04:05PM	Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2026 Outlook (GlobeNewswire)
Dec-31-25 08:07AM	The End of Shots? 5 Biotech Stocks Rethinking Diabetes (PR Newswire)
Dec-01-25 07:00AM	Eledon Pharmaceuticals to Participate in the 37th Annual Piper Sandler Healthcare Conference (GlobeNewswire) -6.13%
Nov-18-25 04:05PM	Eledon Reports Preliminary Data from First Six Patients with Type 1 Diabetes Treated with Tegoprubart as the Core Immunosuppressant Following Islet Transplantation in Investigator-Initiated Trial at UChicago Medicine (GlobeNewswire)
Nov-14-25 05:00PM	Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2025 Financial Results (GlobeNewswire) -7.95%
Nov-12-25 07:56AM	Eledon Pharmaceuticals Announces Pricing of $50 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire) -11.27%
Nov-11-25 05:26PM	Eledon Pharmaceuticals Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire) -5.33%
Nov-06-25 06:30PM	Eledon Presents Phase 2 BESTOW Trial Results for Tegoprubart for the Prevention of Rejection in Kidney Transplantation at the American Society of Nephrology's Kidney Week 2025 Annual Meeting (GlobeNewswire) -49.76%
Nov-05-25 07:00AM	Eledon Pharmaceuticals to Present at Guggenheim Second Annual Healthcare Innovation Conference (GlobeNewswire)
07:00AM	Loading…
Oct-17-25 07:00AM	Eledon Pharmaceuticals to Present Results from Phase 2 BESTOW Trial of Tegoprubart for the Prevention of Rejection in Kidney Transplantation at the American Society of Nephrology Kidney Week 2025 Annual Meeting (GlobeNewswire) +20.70%
Sep-24-25 04:05PM	Eledon Pharmaceuticals to Present at the 18th Congress of the International Xenotransplantation Association (GlobeNewswire) -5.10%
Sep-23-25 07:30AM	2 Strong Buy Stocks That Wall Street Believes Can Soar 360% to 780% (Barchart)
Aug-29-25 07:00AM	Eledon Pharmaceuticals to Participate in Cantor Global Healthcare Conference 2025 (GlobeNewswire)
Aug-14-25 04:20PM	Eledon Pharmaceuticals Reports Second Quarter 2025 Operating and Financial Results (GlobeNewswire)
Aug-06-25 04:01PM	Eledon Presents Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation (GlobeNewswire) +9.90% -20.20%
Jul-31-25 11:40PM	Eledon Pharmaceuticals to Present Updated Clinical Data for Tegoprubart at World Transplant Congress (Insider Monkey) +7.30%
Jul-30-25 04:05PM	Eledon Pharmaceuticals to Host a Conference Call to Discuss Updated Data from the Ongoing Phase 1b Trial of Tegoprubart in Kidney Transplantation Being Presented at the World Transplant Congress 2025 (GlobeNewswire)
Jul-17-25 04:01PM	Updated Data from Eledon Pharmaceuticals' Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation to be Presented at the World Transplant Congress 2025 (GlobeNewswire)
Jul-14-25 10:00AM	Best Momentum Stocks to Buy for July 14th (Zacks) +14.33%
06:09AM	New Strong Buy Stocks for July 14th (Zacks)
Jul-09-25 08:30AM	Sernova Biotherapeutics Announces Collaboration with Eledon Pharmaceuticals to Advance a Potential Functional Cure for Type 1 Diabetes (GlobeNewswire)
Jun-25-25 04:01PM	Eledon Pharmaceuticals to Host R&D Day on July 9, 2025 in New York City (GlobeNewswire)
May-23-25 12:00PM	What Makes Eledon Pharmaceuticals (ELDN) a New Buy Stock (Zacks)
May-14-25 04:01PM	Eledon Pharmaceuticals Reports First Quarter 2025 Operating and Financial Results (GlobeNewswire)
May-03-25 08:15AM	Eledon: A Company With Good Early Data In Kidney Transplant Rejection And A Full Balance Sheet (Seeking Alpha)
Mar-27-25 10:16AM	Is Eledon Pharmaceuticals (ELDN) The Hot Biotech Stock Under $5? (InsiderMonkey)
Mar-20-25 04:01PM	Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Operating and Financial Results (GlobeNewswire)
Mar-04-25 04:05PM	Eledon Pharmaceuticals to Participate in Leerink Partners Global Healthcare Conference (GlobeNewswire)
Feb-07-25 10:00AM	Eledon Pharmaceuticals Announces Use of Tegoprubart as Key Component of Immunosuppression Regimen in its Second Transplant of a Genetically Modified Pig Kidney into a Human (GlobeNewswire)
Jan-29-25 04:05PM	Eledon Pharmaceuticals to Participate in Guggenheim Securities SMID Cap Biotech Conference (GlobeNewswire)
Jan-13-25 07:00AM	Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2025 Outlook (GlobeNewswire)
Nov-12-24 04:01PM	Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2024 Financial Results (GlobeNewswire) -11.41%
Nov-06-24 04:05PM	Eledon Pharmaceuticals to Participate in Guggenheim Securities Inaugural Healthcare Innovation Conference (GlobeNewswire)
Oct-29-24 07:46AM	Eledon Pharmaceuticals Announces Pricing of $85 Million Underwritten Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire) +6.53%
07:45AM	Eledon Pharmaceuticals Announces Positive Initial Data from Subjects with Type 1 Diabetes Treated with Tegoprubart as Part of an Immunosuppression Regimen Following Islet Transplantation in Investigator-Initiated Trial at UChicago Medicine (GlobeNewswire)
Sep-11-24 04:05PM	Eledon Pharmaceuticals to Present at the Cantor Global Healthcare Conference (GlobeNewswire)
Sep-04-24 07:00AM	Eledon Announces Completion of Enrollment in Phase 2 BESTOW Clinical Trial Assessing Tegoprubart for Prevention of Organ Rejection in Kidney Transplant Patients (GlobeNewswire) -5.84%
Aug-14-24 05:21PM	Eledon Pharmaceuticals Reports Preliminary Second Quarter 2024 Operating Results (GlobeNewswire)
Jul-29-24 07:00AM	Eledon Provides Enrollment Update for Phase 2 BESTOW Trial Assessing Tegoprubart for the Prevention of Organ Rejection (GlobeNewswire)
Jul-02-24 04:05PM	Eledon to Participate in the Leerink Partners Therapeutics Forum: I&I and Metabolism (GlobeNewswire)
Jun-17-24 09:36AM	Penny Stock Picks: 3 Companies Poised to Graduate to the Big Leagues (InvestorPlace) -6.93%
Jun-11-24 03:18PM	3 High-Potential Penny Stocks to Turn $1000 into $1 Million: June 2024 (InvestorPlace)
Jun-03-24 04:01PM	Eledon Presents Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation (GlobeNewswire)
May-27-24 09:55AM	Eledon Pharmaceuticals (ELDN) Could Find a Support Soon, Here's Why You Should Buy the Stock Now (Zacks)
May-22-24 12:00PM	Eledon Pharmaceuticals, Inc. (ELDN) is a Great Momentum Stock: Should You Buy? (Zacks)
May-14-24 12:00PM	Eledon Pharmaceuticals (ELDN) Moves to Buy: Rationale Behind the Upgrade (Zacks) +6.85%
May-09-24 01:54PM	ELDN Stock Earnings: Eledon Pharma Beats EPS for Q1 2024 (InvestorPlace)
07:30AM	Eledon Pharmaceuticals Reports First Quarter 2024 Operating and Financial Results (GlobeNewswire)
07:00AM	Eledon Pharmaceuticals to Present Updated Data from Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation at the American Transplant Congress (GlobeNewswire)
May-07-24 07:05AM	Eledon Announces Clinical Progress with Tegoprubart in the Prevention of Transplant Rejection (GlobeNewswire) -7.38%
07:00AM	Eledon Pharmaceuticals Announces Oversubscribed $50 Million Private Placement (GlobeNewswire)
Mar-28-24 04:01PM	Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Operating and Financial Results (GlobeNewswire)
Mar-25-24 04:56PM	Eledon Pharmaceuticals Announces 12th Participant Enrolled in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Organ Rejection (GlobeNewswire)
Mar-21-24 10:31AM	Eledon Pharmaceuticals Announces Use of Tegoprubart in First-ever Transplant of Genetically Modified Kidney from a Pig to a Human (GlobeNewswire) +11.24%
Feb-13-24 07:01PM	Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-04-24 04:40PM	Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2024 Outlook (GlobeNewswire)
Dec-04-23 06:00PM	Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +16.67%
Nov-29-23 04:05PM	Eledon Pharmaceuticals to Present at Noble Capital Markets' Emerging Growth Equity Conference (GlobeNewswire) -6.67%
Nov-09-23 04:01PM	Eledon Pharmaceuticals Reports Third Quarter 2023 Operating and Financial Results (GlobeNewswire)
Nov-08-23 04:05PM	Eledon Pharmaceuticals to Present at Jefferies London Healthcare Conference (GlobeNewswire)
Nov-02-23 09:05AM	Eledon Reports Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation (GlobeNewswire) -10.37%
Oct-23-23 07:00AM	Eledon Pharmaceuticals Strengthens Leadership Team with Appointment of Eliezer Katz, M.D., FACS as Chief Medical Officer (GlobeNewswire)
Oct-13-23 07:00AM	Eledon Pharmaceuticals to Present Data from Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation at the American Society of Nephrology Kidney Week 2023 Annual Meeting (GlobeNewswire)
Oct-02-23 07:00AM	Eledon Pharmaceuticals Appoints Kidney Transplant Specialist Dr. Allan Douglas Kirk to Board of Directors (GlobeNewswire) +13.14%
Sep-25-23 07:00AM	Eledon Pharmaceuticals Announces Use of Tegoprubart anti-CD40L Antibody in Second-ever Transplant of Genetically Modified Heart from a Pig to a Human (GlobeNewswire)
Sep-20-23 04:05PM	Eledon Pharmaceuticals to Participate at the 2023 Cantor Fitzgerald Global Healthcare Conference (GlobeNewswire)
Sep-11-23 07:00AM	Eledon Pharmaceuticals Appoints Industry Veteran James Robinson to its Board of Directors (GlobeNewswire)
Sep-06-23 07:00AM	Eledon Pharmaceuticals Announces Publication of Data Showing Treatment with Tegoprubart Promotes Kidney and Islet Allograft Survival and Function in Nonhuman Primates (GlobeNewswire) -11.89%
Sep-05-23 07:00AM	Eledon Pharmaceuticals Announces First Participant Dosed in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Rejection in Kidney Transplantation (GlobeNewswire)
Aug-16-23 07:00AM	Eledon Pharmaceuticals Announces Dosing of 10th Patient in Ongoing Phase 1b Trial Evaluating Tegoprubart in Patients Undergoing Kidney Transplantation (GlobeNewswire)
Aug-10-23 07:00AM	Eledon Pharmaceuticals Reports Second Quarter 2023 Operating and Financial Results (GlobeNewswire)
Jul-12-23 07:30AM	Amerigo Reports Q2-2023 Production Results and Provides MVC Operational Update (GlobeNewswire)
Jun-02-23 08:00AM	Eledon Pharmaceuticals to Present at Jefferies Healthcare Conference (GlobeNewswire)
May-11-23 04:01PM	Eledon Pharmaceuticals Reports First Quarter 2023 Operating and Financial Results (GlobeNewswire) -13.00%
May-04-23 04:05PM	Eledon Pharmaceuticals to Report First Quarter 2023 Financial Results on Thursday, May 11, 2023 (GlobeNewswire) +6.33% +6.35%
May-01-23 07:00AM	Eledon Pharmaceuticals Announces up to $185 Million Financing to Advance Tegoprubart Kidney Transplantation Clinical Trials (GlobeNewswire) +9.52%
Apr-05-23 07:46PM	Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-31-23 06:00AM	Eledon Reports Data from Ongoing Phase 1b Trial Evaluating Tegoprubart in Patients Undergoing Kidney Transplantation at World Congress of Nephrology (GlobeNewswire) -5.98%
Mar-30-23 04:01PM	Eledon Pharmaceuticals Reports Fourth Quarter and Full-Year 2022 Operating and Financial Results (GlobeNewswire) +5.91%

Show Previous News

Insider Trading	Relationship	Date	Transaction	#Shares	#Shares Total	SEC Form 4
McBride John S.	Director	Jan 10 '26	Option Exercise	3,430	3,430	Jan 16 05:00 PM
Hillson Jan	Director	Jan 10 '26	Option Exercise	3,430	3,430	Jan 16 05:00 PM
Kirk Allan	Director	Jan 10 '26	Option Exercise	3,430	3,430	Jan 16 05:00 PM
Katkin Keith	Director	Jan 10 '26	Option Exercise	8,575	8,575	Jan 16 05:00 PM
Lee June	Director	Jan 10 '26	Option Exercise	3,430	3,430	Jan 16 05:00 PM
Robinson James A. Jr.	Director	Jan 10 '26	Option Exercise	3,430	3,430	Jan 16 05:00 PM

Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company, which engages in development of therapies to protect transplanted organs and prevent rejection. The firm also focuses on development of therapy to treat amyotrophic lateral sclerosis. Its compound in development is tegoprubart, a humanized IgG1 anti-CD40L antibody with high affinity for CD40 ligand (CD40L), a biological target with broad therapeutic potential. The company was founded on March 26, 2004 and is headquartered in Irvine, CA.

Ph.D.Dr. David-Alexandre C. Gros M.D.

PresidentDr. Steven N. Perrin Ph.D.

Chief Financial OfficerMr. Paul Sean Little

Vice President of Technical OperationsMr. John Herberger

General CounselMr. Bryan E. Smith J.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ELDN

Eledon Pharmaceuticals Inc

Upgrade your Finviz experience